Kim Edmonds

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal.

Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal.

Journal: Cancer discovery

Published: April 09, 2024

Tracking non-genetic evolution from primary to metastatic ccRCC: TRACERx Renal.

Tracking non-genetic evolution from primary to metastatic ccRCC: TRACERx Renal.

Journal: Cancer discovery

Published: April 09, 2024

Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.

Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.

Journal: Cell reports. Medicine

Published: August 16, 2023

Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.

Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.

Journal: Cancer discovery

Published: December 20, 2022

REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers.

REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers.

Journal: Contemporary clinical trials

Published: July 25, 2022

Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.

Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.

Journal: Cell reports. Medicine

Published: June 06, 2022

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.

Journal: Cancer cell

Published: April 12, 2022

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.

Journal: Cancer cell

Published: March 30, 2022

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.

Journal: Cancer cell

Published: December 30, 2021

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.

Journal: Lancet (London, England)

Published: December 29, 2021

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.

Journal: Nature cancer

Published: December 24, 2021

Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.

Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.

Journal: Research square

Published: September 28, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026